Navigation Links
Angeion Corporation Reports Third Quarter Fiscal 2011 Operating Results

SAINT PAUL, Minn., Sept. 1, 2011 /PRNewswire/ -- Angeion Corporation (NASDAQ: ANGN) today reported financial results for its fiscal third quarter ended July 31, 2011.

Angeion reported revenues of $6.8 million compared to $7.1 million in the third quarter of fiscal 2010. Angeion incurred a net loss of $81,000, or $(0.02) per diluted share versus net income of $126,000, or $0.03 per diluted share in the comparable quarter last year. Financial results for Q3 2011 were impacted by severance charges and associated legal and consulting fees attributable to the departure of the previous chief executive officer.

Gross margin for the quarter remained solid at 57.6%, comparable to the 57.8% gross margin in the third quarter of fiscal year 2010. General and administrative expenses in Q3 2011 decreased 20% versus the prior year comparable quarter due to lower severance expenses in the just completed quarter versus the prior year third quarter. Management will continue to examine overhead expenses going forward to move the company on a path toward profitability. Sales and marketing expenses were essentially the same compared to the third quarter of fiscal 2010 and research and development costs increased 32% as management dedicated additional resources to advance software and hardware development initiatives to enhance current product offerings and develop future new products.

“Bringing stability to Angeion as an operating company is well underway,” said Gregg O. Lehman, Ph.D., President and Chief Executive Officer of Angeion Corporation. “Change is needed to become a consistently profitable company and we are examining every aspect of the Company to determine where improvements need to be made. Angeion has been impacted in recent years by changes in its management resulting in multiple severance and related charges. We are now realizing stability and have a dedicated and talented management team in place. We are in the initial stages of instituting our business plan that will result in disciplined and efficient operations, with a focus on innovation, automation, expense reduction and ultimately capturing a larger market share through a renewed strategic marketing focus,” continued Lehman.

During the quarter the Company bought back a total of approximately 34,000 shares of Angeion common stock in the open market for $148,000. The Company intends to continue to repurchase its shares under the stock repurchase program, which has a remaining authorization of $2.85 million.

As of July 31, 2011 the Company reported cash, equivalents and short term investments totaling $9.0 million and no long-term debt. For the nine-month period, 22% of the Company’s equipment sales were placed in the facilities of new customers as the sales and marketing team focuses its efforts to gain market share.

Dr. Lehman continued, “Angeion Corporation has the necessary attributes to be a successful and consistently profitable company. We have a strong product line, market leading customer service and technical support, loyal customers and dedicated employees. Our number one mission will be the implementation and the on-going execution of highly disciplined business processes, with a strong focus on cost/benefit analysis, to guide the future direction of our product development and technical service support and to analyze opportunities for new markets and product lines going forward. We will be long-term participants in all the markets where we compete and we expect to be among the leaders in those markets. There are great opportunities ahead and we expect to capitalize on those opportunities to grow Angeion and to deliver enhanced shareholder value in the coming years.”

Conference CallThe Company has scheduled a conference call for September 1, 2011 at 4:30 pm ET to discuss its financial results for the third quarter of fiscal year 2011.

Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet webcast available at A replay of the conference call will be available by dialing (877) 344-7529 or (412) 317-0088, confirmation code 10003350, through September 7, 2011. A webcast replay of the conference call will be accessible at for 30 days.

About Angeion CorporationFounded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics ( and New Leaf ( brand names. These cardiorespiratory product lines provide solutions for disease detection, integrated care, and wellness across the entire spectrum of health – whether managing chronic illness, promoting fitness, or training for the Olympics. The Company’s products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians’ offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit

Forward Looking StatementsPress releases and other statements by Angeion may contain forward-looking statements about Angeion’s future financial results and business prospects that by their nature involve substantial risks and uncertainties. You can identify these statements by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “project,” “intend,” “plan,” “will,” “target,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects. Our actual results may differ materially depending on a variety of factors including: (1) national and worldwide economic and capital market conditions; (2) continuing cost-containment efforts in our hospital, clinics, and office market; (3) any changes in the patterns of medical reimbursement that may result from national healthcare reform; (4) our ability to successfully operate our business, including successfully converting our increasing research and development expenditures into new and improved cardiorespiratory diagnostic products and services and selling these products and services under the MedGraphics and New Leaf brand names into existing and new markets; (5) our ability to complete our  software development initiatives and migrate our MedGraphics and New Leaf platforms to a next generation technology; (6) our ability to maintain our cost structure at a level that is appropriate to our near to mid-term revenue expectations and that will enable us to increase revenues and profitability as opportunities develop; (7) our ability to achieve constant margins for our products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers; (8) our ability to expand our international revenue through our distribution partners and our Milan, Italy representative branch office; (9) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products; (10) our ability to defend our existing intellectual property and obtain protection for intellectual property we develop in the future; (11) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures; (12) our dependence on third-party vendors and (13) the ability of new members of our senior management to make a successful transition into their new roles and for all members of senior management to ultimately develop and implement a strategic plan. Additional information with respect to the risks and uncertainties faced by the Company may be found in, and the above discussion is qualified in its entirety by, the other risk factors that are described from time to time in the Company’s Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2010. Contact:

Robert M. Wolf

Joe Dorame, Robert Blum, Joe DiazAngeion Corporation

Lytham Partners, LLCChief Financial Officer

(602) 889-9700(651) 766-4874

angn@lythampartners.comANGEION CORPORATION AND SUBSIDIARIESConsolidated Balance SheetsJuly 31, 2011 and October 31, 2010(In thousands except share and per share data)July 31,2011October 31,2010ASSETS(Unaudited)Current Assets:Cash and cash equivalents$   8,084$   6,943Short-term investments9642,721Accounts receivable, net of allowance for doubtful accounts of $46 and $100, respectively4,7015,221Inventories, net of obsolescence reserve of $572 and $599, respectively4,1313,697Prepaid expenses and other current assets 246270Total Current Assets18,12618,852Noncurrent investments-722Property and equipment, net of accumulated depreciation of $3,706 and $3,649, respectively492528Intangible assets, net1,2041,279Total Assets$  19,822$  21,381LIABILITIES AND SHAREHOLDERS' EQUITYCurrent Liabilities:Accounts payable$   1,819$   1,951Employee compensation1,1872,115Deferred income1,7701,522Warranty reserve115175Other current liabilities and accrued expenses300408Total Current Liabilities5,1916,171Long-term Liabilities:Long-term deferred income and other761873Total Liabilities5,9527,044Commitments and Contingencies--Shareholders' Equity:Common Stock, $0.10 par value, authorized 25,000,000 shares, 3,897,243 and 3,862,113 shares issued and 3,768,417 and 3,747,454 shares outstanding at 2011 and 2010, respectively377375Additional paid-in capital20,56320,486Accumulated deficit(7,074)(6,531)Accumulated other comprehensive income47Total Shareholders' Equity13,87014,337Total Liabilities and Shareholders' Equity$  19,822$  21,381ANGEION CORPORATION AND SUBSIDIARIESConsolidated Statements of Operations(Unaudited, in thousands except per share data)Three Months EndedJuly 31,Nine Months EndedJuly 31,2011201020112010RevenuesEquipment and supply sales$
7,958Service revenues1,0869132,9822,6316,8477,12020,70020,589Cost of revenuesCost of equipment and supplies2,5162,6197,7478,331Cost of service revenue3843851,1321,2122,9003,0048,8799,543Gross margin3,9474,11611,82111,046Operating expenses:Selling and marketing1,9951,9676,1215,810General and administrative9141,1423,2193,295Research and development1,0127682,6752,867Amortization of intangibles1051053153154,0263,98212,33012,287Operating (loss) income(79)134(509)(1,241)Other expense(2)-(24)-Interest income, net10-206(Loss) income before income taxes(71)134(513)(1,235)Provision for income taxes1083024Net (loss) income$
(1,259)(Loss) income per share:Basic$
(0.30)Weighted average common shares outstanding:Basic3,7924,1313,7724,145Diluted3,7924,2413,7724,145ANGEION CORPORATION AND SUBSIDIARIESConsolidated Statements of Cash Flows(Unaudited, in thousands)Nine Months EndedJuly 31,20112010Cash flows from operating activities:Net loss$
(543)$  (1,259)Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation and amortization514584Stock-based compensation198576(Decrease) increase in allowance for doubtful accounts(54)(13)(Decrease) increase in inventory obsolescence reserve(27)20Loss on disposal of equipment24-Change in operating assets and liabilities:Accounts receivable574(319)Inventories(407)327Prepaid expenses and other current assets2453Accounts payable(132)21Employee compensation(928)46Deferred income136(36)Warranty reserve(60)(8)Other current liabilities and accrued expenses(108)84Net cash (used in) provided by operating activities(789)76Cash flows from investing activities:Sales (purchases) of investments2,476(3,436)Purchases of property and equipment and intangible assets(427)(251)Net cash provided by (used in) investing activities2,049(3,687)Cash flows used in financing activities:Proceeds from issuance of common stock under employee stock purchase plan2018Proceeds from the exercise of stock options487Repurchase of common stock(148)(299)Repurchase of common stock upon vesting of restricted stock grants(39)(60)Net cash used in financing activities(119)(334)Net increase (decrease) in cash and cash equivalents1,141(3,945)Cash and cash equivalents at beginning of period6,94311,219Cash and cash equivalents at end of period$   8,084$   7,274

SOURCE Angeion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Angeion Corporation to Report Third Quarter Fiscal Year 2011 Financial Results on Thursday, September 1, 2011
2. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
3. CEL-SCI Corporation Releases Letter to Shareholders
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
6. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
7. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
8. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
9. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
11. Immunosyn Corporation Releases SF-1019 Study Results
Post Your Comments:
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a ... targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Lori R. ... a member of ElderCounsel, a national organization of elder law and special needs planning ... laws and rules. It also provides a forum to network with elder law attorneys ...
(Date:10/13/2017)... ... ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to host ... items from across the nation, this holiday-themed event will raise funds and awareness for ... The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 p.m.) ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
Breaking Medicine News(10 mins):